Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
Rhea-AI Summary
Vaxcyte (Nasdaq: PCVX) will report Q4 and full-year 2025 financial results and provide a business update on February 24, 2026 after market close. Management will host a conference call and webcast at 4:30 p.m. ET / 1:30 p.m. PT.
A live webcast will be available on the company website and a replay will be accessible for about 30 days.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
PCVX fell 1.03% with mixed moves among biotech peers: ACAD, ARWR, KRYS and MTSR down while ACLX gained. This points to stock-specific trading rather than a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 05 | Conference participation | Positive | +4.2% | Guggenheim biotech summit fireside chat with webcast access for investors. |
| Feb 02 | Equity offering close | Negative | -2.9% | Closing of $632.5M underwritten public offering including full underwriter option. |
| Jan 29 | Offering pricing | Negative | +2.8% | Pricing of $550M public offering of common stock at $50 per share. |
| Jan 29 | Offering launch | Negative | +2.8% | Commencement of proposed $500M common stock and pre-funded warrants offering. |
| Jan 22 | Clinical program update | Positive | +7.2% | Advancement of VAX-31 adult Phase 3 and infant Phase 2 vaccine programs. |
Recent substantive program updates and offerings often saw notable moves, with positive clinical news generally aligning with upside and financing events showing mixed reactions.
Over recent months, Vaxcyte has balanced clinical and corporate milestones. On Jan 22, 2026, it advanced its VAX-31 adult and infant programs, with shares rising 7.19%. Multiple equity offerings in late January and early February provided substantial capital, but produced mixed price reactions, including moves of -2.91% and +2.82%. A Guggenheim summit appearance on Feb 5, 2026 coincided with a 4.16% gain. Today’s earnings date notice fits into this cadence of regular updates rather than a major new catalyst.
Market Pulse Summary
This announcement sets the timetable for Vaxcyte’s Q4 and full-year 2025 update on February 24, 2026, with management hosting a call at 4:30 p.m. ET. In recent months the company combined major clinical progress, notably in its VAX-31 program, with substantial equity offerings to fund development. Investors following this date may focus on updated cash levels, spending trends and any changes to development timelines or manufacturing plans.
AI-generated analysis. Not financial advice.
SAN CARLOS, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today that it will report financial results for the fourth quarter and full year 2025 and provide a business update after market close on February 24, 2026. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT.
To participate in the conference call, please dial 800-445-7795 (domestic) or 785-424-1699 (international), conference ID PCVX4Q25. A live webcast of the conference call will be available in the Investors & Media section of the Company’s website at www.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference call.
About Vaxcyte
Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in a Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-31 and VAX-24 are designed to improve upon standard-of-care PCVs by covering the serotypes in circulation that cause a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains. VAX-XL, in earlier-stage development, also leverages the Company’s carrier-sparing, site-specific conjugation technology with the aim of further expanding coverage to deliver the broadest-spectrum candidate in the Company’s PCV franchise.
Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF®, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to develop high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella. For more information, visit www.vaxcyte.com.
Contacts:
Patrick Ryan, Executive Director, Corporate Affairs
Vaxcyte, Inc.
415-606-5135
media@vaxcyte.com
Jeff Macdonald, Executive Director, Investor Relations
Vaxcyte, Inc.
917-371-0940
investors@vaxcyte.com
FAQ
When will Vaxcyte (PCVX) release its Q4 and full-year 2025 results?
What time is the Vaxcyte (PCVX) conference call and webcast on February 24, 2026?
How can investors join the Vaxcyte (PCVX) conference call for Q4 2025 results?
Will a replay of the Vaxcyte (PCVX) webcast be available after the February 24, 2026 call?
Where can I find the Vaxcyte (PCVX) webcast and investor materials for the February 24, 2026 update?
